13058_2019_1121_MOESM2_ESM.tif (3.23 MB)
Additional file 2: of The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours
figure
posted on 2019-02-28, 05:00 authored by Arian Lundberg, Linda LindstrĂśm, Jingmei Li, J. Harrell, Eva Darai-Ramqvist, Emmanouil Sifakis, Theodoros Foukakis, Charles Perou, Kamila Czene, Jonas Bergh, Nicholas TobinFigure S2. Survival analysis (KaplanâMeier estimates) with breast cancer-specific survival (BCSS) as a clinical end point for all patients of cohort 1 split by PAM50 subtypes and treatments. (A) Luminal A, (B) luminal B, (C) HER2-enriched, (D) basal-like, (E) endocrine therapy, (F) chemotherapy, (G) both chemotherapy and endocrine combined, (H) untreated patients. P values refer to log-rank tests. (TIF 3311 kb)